Five-Year Incidence and Visual Outcomes in Postintravitreal Injection Endophthalmitis

Although intravitreal injections are considered a great advancement in the management of retinal diseases because they have potential to improve vision, endophthalmitis is a concern to a treating ophthalmologist.1,2 Previous studies have found a prevalence of postinjection endophthalmitis of 0% to 0.87%. The purpose of this study is to report the incidence, microbiological profile, antimicrobial susceptibility, clinical findings, management, and visual outcomes in patients with acute postinjection endophthalmitis (within 6 weeks) after anti-vascular endothelial growth factor and intravitreal injection of triamcinolone acetonide (IVTA).